Drug intelligence / Profile preview

cyclophosphamide + fludarabine phosphate + mycophenolate mofetil + tacrolimus

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination immunosuppressive regimen used primarily in transplantation medicine, particularly for preventing graft-versus-host disease (GVHD) in stem cell transplantation. This multi-drug approach works through complementary mechanisms to suppress the immune system and has shown effectiveness in preventing both acute and chronic GVHD after allogeneic peripheral blood stem cell transplantation from HLA-matched donors.

Targets

FKBP1ACN (Calcineurin)RNR (Ribonucleotide reductase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)DNA polymerase familyDNA

Beyond the preview

Go deeper on cyclophosphamide + fludarabine phosphate + mycophenolate mofetil + tacrolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + fludarabine phosphate + mycophenolate mofetil + tacrolimus.

Explore the full profile